We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $5.34B
1-Year Est. Return 380.18%
This Fund
S&P 500
This Quarter Est. Return
+24.96%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.96B
AUM Growth
+$343M
Cap. Flow
-$238M
Cap. Flow %
-8.04%
Top 10 Hldgs %
65.85%
Holding
44
New
9
Increased
15
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$43.6M
2
VERA icon
Vera Therapeutics
VERA
+$41.6M
3
PLRX icon
Pliant Therapeutics
PLRX
+$38.8M
4
JANX icon
Janux Therapeutics
JANX
+$36.4M
5
ONC
BeOne Medicines Ltd
ONC
+$36M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$150M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$95.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$90.6M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$79.7M
5
IRON icon
Disc Medicine
IRON
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.67%
2 Miscellaneous 3.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$512M 17.3%
5,000,000
+428,322
+9% +$35.5M
ACLX
2
DELISTED
Arcellx
ACLX
$334M 11.3%
4,000,000
+151,905
+4% +$10.1M
ARGX icon
3
argenx
ARGX
$62.7B
$260M 8.81%
480,374
-57,765
-11% -$29.2M
RVMD icon
4
Revolution Medicines
RVMD
$44.5B
$241M 8.15%
5,314,089
+55,000
+1% +$2.39M
CRNX
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$129M 4.35%
2,516,686
+3,384
+0.1% +$175K
MRUS
6
DELISTED
Merus
MRUS
$123M 4.15%
2,454,917
+435,103
+22% +$22.7M
JANX icon
7
Janux Therapeutics
JANX
$1.18B
$109M 3.69%
2,400,574
+836,122
+53% +$36.4M
KURA icon
8
Kura Oncology
KURA
$1.08B
$84.6M 2.86%
4,331,321
-208,060
-5% -$4.22M
TARS icon
9
Tarsus Pharmaceuticals
TARS
$3.63B
$80.3M 2.72%
2,440,445
+5,029
+0.2% +$141K
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.71B
$74.4M 2.52%
2,789,172
+463,723
+20% +$9.22M
IRON icon
11
Disc Medicine
IRON
$2.94B
$73.6M 2.49%
1,497,720
-1,206,998
-45% -$56.7M
PCVX icon
12
Vaxcyte
PCVX
$8.86B
$71.7M 2.43%
627,732
+530
+0.1% +$47.8K
ACLX
13
CALL
DELISTED
Arcellx
ACLX
$66.8M 2.26%
+800,000
New +$53.3M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.58B
$65.9M 2.23%
2,895,689
-660
-0% -$10.8K
OLMA icon
15
Olema Pharmaceuticals
OLMA
$906M
$65.7M 2.22%
5,503,600
-2,400,000
-30% -$30.7M
ARVN icon
16
Arvinas
ARVN
$573M
$57.6M 1.95%
2,339,961
-98,188
-4% -$2.56M
YMAB
17
DELISTED
Y-mAbs Therapeutics
YMAB
$53.7M 1.82%
4,086,346
+215,752
+6% +$2.73M
COGT icon
18
Cogent Biosciences
COGT
$5.93B
$49.8M 1.68%
4,609,762
+985,420
+27% +$9.59M
VERA icon
19
Vera Therapeutics
VERA
$2.43B
$48.5M 1.64%
+1,096,851
New +$41.6M
MLTX icon
20
MoonLake Immunotherapeutics
MLTX
$1.17B
$47M 1.59%
+931,480
New +$43.6M
ONC
21
BeOne Medicines Ltd
ONC
$39.7B
$45M 1.52%
+200,336
New +$36M
IMTX icon
22
Immatics
IMTX
$1.39B
$44.6M 1.51%
3,904,862
+482,897
+14% +$5.72M
APGE
23
DELISTED
Apogee Therapeutics
APGE
$41.2M 1.39%
701,817
+371,817
+113% +$17.8M
IMVT icon
24
Immunovant
IMVT
$8B
$38.9M 1.31%
1,362,827
– –
CGEM icon
25
Cullinan Oncology
CGEM
$1.37B
$38.9M 1.31%
2,321,013
+778,208
+50% +$13.8M
1
2

Similar funds

FFB
First Financial Bankshares Abilene, Texas $5.34B AUM 28.75% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
CAU
Caxton Associates (UK) London $5.33B AUM 59.38% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $5.31B AUM 55.82% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Paradigm Biocapital Advisors held 44 positions worth $2.96B, up 13% from $2.61B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Paradigm Biocapital Advisors withdrew a net $238M in Q3 2024, closing 11 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $150M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Paradigm Biocapital Advisors opened a new position in MoonLake Immunotherapeutics worth $47M.

  • Paradigm Biocapital Advisors's largest Q3 2024 buy was MoonLake Immunotherapeutics: 931,480 shares worth $47M.
  • Paradigm Biocapital Advisors added most to Janux Therapeutics in Q3 2024, an estimated $36.4M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2024 reduction was Disc Medicine, cutting an estimated $56.7M.
  • Paradigm Biocapital Advisors fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $150M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 66% of its $2.96B portfolio in Q3 2024.
  • Paradigm Biocapital Advisors opened 9 new positions and closed 11 in Q3 2024.
  • Paradigm Biocapital Advisors's portfolio value rose 13% quarter-over-quarter to $2.96B.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.